This page shows the latest cancer news and features for those working in and with pharma, biotech and healthcare.
In February, Janssen revealed additional results for Erleada, this time in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). ... In the EU, Erleada is approved for the treatment of
see patient versions of Abbott’s i-STAT device. Out of the home, innovations like Philip’s Ingenia are enabling early cancer detection by integrating MRI and CT scans, which of
An interim analysis of the EMERGE study found that vopratelimab in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) in non-small cell lung cancer (NSCLC) patients who had previously been
most common form of kidney cancer. ... now with a new immunotherapy and tyrosine kinase inhibitor regimen,” said Dana Walker, vice president, development programme lead, genitourinary cancers, BMS.
in non-small cell lung cancer (NSCLC) at the virtual American Association for Cancer Research (AACR) annual meeting. .
including pancreatic, colon, breast and salivary cancer, with 62.5% having gastrointestinal tumours. ... These findings further demonstrate the importance of broad tumour profiling in advanced cancers,” he added.
More from news
Approximately 715 fully matching, plus 3,150 partially matching documents found.
Its application to major congresses across all medical disciplines – from cancer to cardiovascular, respiratory to rheumatology – will undoubtedly continue.
In some areas, such as gene therapies and high-cost cancer treatments, accelerated approval and early access schemes are conditional on capturing real-world outcomes data – and patient support tools provide
Pancreatic Cancer. HCPs shared, mentioned and interacted with these groups, reflecting the trust that exists between them. ... has been a key driver of the online HCP conversation around pancreatic cancer.
When UroGen received FDA approval for Jelmyto (mitomycin gel) in April 2020, the drug became the first therapy approved to treat low-grade upper tract urothelial cancer (UTUC).
The most promising results seen to date show that genetic information has helped boost the survival rates of those suffering from advanced non-small-cell lung cancer by four to five
More from intelligence
Approximately 8 fully matching, plus 339 partially matching documents found.
promise to create, develop and bring truly differentiated next-generation antibody medicines to cancer patients,” he added.
newly-diagnosed non-small cell lung cancer (NSCLC) patients.
Prior to McCann Health France, she served as scientific director at various international health organisations, including the ARC Foundation for Cancer Research and the French National Cancer Institute.
Anthony shares our determination to bring truly differentiated new cancer treatments to the market that will deliver on our commitment to improve patients’ lives while fostering a culture of excellence and
Galecto. Galecto, a clinical stage company developing treatments for fibrosis and cancer, has appointed Bertil Lindmark as its new chief medical officer.
More from appointments
Approximately 5 fully matching, plus 209 partially matching documents found.
I covered biological mechanisms of how chemotherapy works, what cancer actually is, and different mechanisms of detecting cancer in the blood.
5. Many of the most common health conditions affecting men including coronary heart disease, diabetes and various cancers are also known to be affected by these habits. ... 10. This includes:. Supporting research efforts for male-specific diseases such
in cancer biology and she has experience working as a research technician in the field of malignant haematology. .
3. The Eve Appeal, a charity for gynaecological cancers, found in a survey of healthcare professionals that 47% agreed that women not knowing the correct terminology for their reproductive anatomy could ... Women are unnecessarily dying in childbirth or
Well, not necessarily. According to a survey study from late December, 78% of the 92 surveyed participants had never used social media as a patient recruitment method for cancer clinical trials.
More from PMHub
Approximately 43 fully matching, plus 207 partially matching documents found.
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...